These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11122270)

  • 1. Variation in inhibitor reactivity in acquired haemophilia A with different concentrates.
    Sukhu K; Keeling DM; Giangrande PL
    Clin Lab Haematol; 2000 Oct; 22(5):287-90. PubMed ID: 11122270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
    Kallas A; Talpsep T
    Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
    Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
    Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A.
    Lindgren A; Wadenvik H; Tengborn L
    Haemophilia; 2002 Sep; 8(5):644-8. PubMed ID: 12199673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired haemophilia syndrome: pathophysiology and therapy.
    Elezović I
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.
    Martin PG; Sukhu K; Chambers E; Giangrande PL
    Clin Lab Haematol; 1999 Apr; 21(2):125-8. PubMed ID: 10342072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.